|
- SynerVax™ vaccine adjuvant is based on a proprietary methodology for complexing antigens with alpha-2-macroglobulin
(alpha2M). The resulting vaccines are much more effectively processed by antigen presenting cells, resulting in enhanced
immune responses.
- Synergy’s enabling technology platform allows for the efficient incorporation of antigens into
alpha2M. This process is so gentle that it maintains antigen integrity, adds stability, prolongs shelf life and avoids the
"cold chain" requirement for shipping and storage.
- SynerVax™ vaccine adjuvant lowers vaccine dosage by an order
of magnitude or more with corresponding reductions in vaccine costs and side effects.
- SynerVax™ vaccine adjuvant
shields antigens from proteases or existing antibodies until they are taken up, in a receptor-specific manner, by the appropriate
immune cells.
- SynerVax™ vaccine adjuvant is a safe, natural, and extremely effective way to elicit extremely
strong antibody and CTL responses to subunit antigens.
|
